These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 19369120)
41. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428 [TBL] [Abstract][Full Text] [Related]
42. Mycobacterium haemophilum infection after alemtuzumab treatment. Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587 [No Abstract] [Full Text] [Related]
43. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199 [TBL] [Abstract][Full Text] [Related]
44. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD. Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253 [TBL] [Abstract][Full Text] [Related]
45. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Thachil J; Jadhav V; Gautam M; McKew S; Arumainathan A; Collins D; Smyth C; Harper J; Pettitt A Br J Haematol; 2007 Aug; 138(4):559-60. PubMed ID: 17587337 [No Abstract] [Full Text] [Related]
46. [A new therapeutic alternative in chronic B-lymphocytic leukemia]. Portal E Rev Infirm; 2002 Dec; (86):38-40. PubMed ID: 12630232 [No Abstract] [Full Text] [Related]
47. Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells. Liebner S; Kniesel U; Kalbacher H; Wolburg H Eur J Cell Biol; 2000 Oct; 79(10):707-17. PubMed ID: 11089919 [TBL] [Abstract][Full Text] [Related]
57. Claudin expression modulations reflect an injury response in the murine epidermis. Arabzadeh A; Troy TC; Turksen K J Invest Dermatol; 2008 Jan; 128(1):237-40. PubMed ID: 17625592 [No Abstract] [Full Text] [Related]
58. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation. van der Velden VH Haematologica; 2006 Mar; 91(3):291A. PubMed ID: 16531248 [No Abstract] [Full Text] [Related]
59. Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood. Hale G Transfus Sci; 1999 Dec; 21(3):181-4. PubMed ID: 10848438 [No Abstract] [Full Text] [Related]
60. Lymphocyte depletion for kidney transplantation: back to the past? Cravedi P; Mannon RB; Remuzzi G Nat Clin Pract Nephrol; 2008 Oct; 4(10):534-5. PubMed ID: 18725917 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]